JB Chemicals non-executive director Sanjay Nayar steps down

Published On 2022-01-27 06:15 GMT   |   Update On 2022-01-27 12:59 GMT

Mumbai: J. B. Chemicals & Pharmaceuticals Ltd. has recently announced that Mr. Sanjay Nayar, non-executive director, has resigned as a director of the company effective January 25, 2022."This is to inform you that Mr. Sanjay Nayar, non-executive director, has resigned as a director of J. B. Chemicals & Pharmaceuticals Ltd. effective January 25, 2022 due to other commitments,"...

Login or Register to read the full article

Mumbai: J. B. Chemicals & Pharmaceuticals Ltd. has recently announced that Mr. Sanjay Nayar, non-executive director, has resigned as a director of the company effective January 25, 2022.

"This is to inform you that Mr. Sanjay Nayar, non-executive director, has resigned as a director of J. B. Chemicals & Pharmaceuticals Ltd. effective January 25, 2022 due to other commitments," the company said in a BSE filing.

" Sanjay Nayar is Chairman of KKR India. He joined KKR in 2009 and was Partner & CEO of KKR India until January 2021. Prior to joining KKR, he served as CEO of Citigroup's Indian and South Asian operations," reads details of Nayar on JB Chemicals' official site.

He was a member of Citigroup's Management Committee and Asia Executive Operating Committee from 2002 – 2009. Mr. Nayar also served Citibank/Citigroup for 25 years in various positions in India, UK, and USA. Mr. Nayar is a member of the Board of US-India Strategic Partnership Forum (USISPF), the Governing Board of Indian School of Business (ISB), is an Executive Member of CII PE/VC Committee, and as recently as November 2020 tenured from SEBI's NISM Board of Governors after six years. He has obtained a B.Sc. (Hons) from the Delhi College of Engineering and an MBA (Finance) from the Indian Institute of Management, Ahmedabad.    

Founded in 1976, J.B. Chemicals & Pharmaceuticals Laboratories (JBCPL) is a pharmaceutical company headquartered in India. In India, the Company has five brands among the top 300 brands in the country. The Company exports its finished formulations to over 30 countries including the USA. It has seven state-of-the-art manufacturing facilities in India including a dedicated manufacturing facility for medicated lozenges. The manufacturing facilities are certified by leading regulators across the world. 

Read also: JB Chemicals to strike Rs 628 crore deal with Sanzyme for probiotic, reproductive brands

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News